세균 백신 시장 규모, 점유율, 성장 및 세계 산업 분석 : 유형별, 용도별, 지역별 인사이트 및 예측(2024-2032년)

Growth Factors of bacterial vaccines Market

The global bacterial vaccines market is experiencing robust growth due to rising incidence of bacterial infections, advancements in vaccine technology, and increasing awareness of preventive healthcare. The market was valued at USD 27.23 billion in 2024, projected to grow to USD 29.68 billion in 2025, and expected to reach USD 62.66 billion by 2032, demonstrating a strong upward trajectory. North America dominated the market in 2024, accounting for 55.67% of the global share, supported by widespread vaccination initiatives, substantial healthcare spending, and strong research and development infrastructure.

Market Dynamics and Drivers

Bacterial vaccines are designed to protect individuals from bacterial infections by stimulating the immune system to recognize and combat bacterial pathogens. Rising global prevalence of bacterial diseases such as diphtheria, tetanus, pertussis, and pneumococcal infections has created a strong demand for effective vaccines. Increased population density and migration patterns further contribute to the spread of bacterial infections, encouraging higher adoption of vaccination programs.

Government initiatives, awareness campaigns, and rising healthcare investments are key drivers of growth. For instance, targeted bacterial vaccines are being explored for innovative applications such as cancer immunotherapy, where they train the immune system to identify and attack cancer cells, further expanding market potential.

Market Challenges and Restraints

Regulatory hurdles remain a significant challenge in the bacterial vaccines market. Vaccine development involves lengthy clinical trials and approval timelines, often spanning 10-15 years, with costs running into millions of dollars per product. Regulatory requirements vary across countries, complicating global approvals. Additionally, pricing constraints in the private sector-such as the Meningococcal vaccine cost of USD 189.35 per dose (CDC, June 2025)-may limit profitability, which could restrain market growth.

The complexity of bacterial pathogens also poses challenges. Bacteria possess diverse antigens, making it difficult to identify which antigens will trigger long-lasting immune responses. This requires substantial investment in research and development, impacting the speed of new product introduction.

Market Opportunities

The rise in antimicrobial resistance (AMR) offers lucrative growth opportunities. With over 70% of major bacterial strains exhibiting antibiotic resistance, vaccines provide a preventive solution, reducing reliance on antibiotics and slowing the emergence of drug-resistant pathogens. Global funding initiatives, such as CARB-X, are investing heavily in bacterial vaccine development, highlighting the market's potential for growth.

Trends in the Market

A major trend in the market is the development of thermostable vaccines, capable of remaining stable in extreme temperatures ranging from -20°C to +40°C. Such innovations reduce dependency on cold-chain logistics and increase vaccine accessibility, particularly in emerging economies. For example, Stablepharma initiated human trials for SPVX02, the world's first fridge-free bacterial vaccine, in April 2025. Thermostable vaccines are increasingly being targeted for pediatric vaccines, including pneumococcal and Hib vaccines.

Segmentation Analysis

By type, the recombinant/conjugate/subunit segment dominated in 2024 due to its efficacy, long-term protection, and simplified manufacturing process. The inactivated segment is the second-largest and is growing due to its stability and suitability for immunocompromised individuals.

By route of administration, parenteral vaccines led the market in 2024 because of higher efficacy and government-supported immunization campaigns. Oral vaccines are emerging as a fast-growing segment due to ease of administration, safety, and cost advantages.

By age group, the pediatric segment dominated in 2024, driven by rising birth cohorts and extensive immunization programs, including the DTP3 vaccine, which reached 84% global coverage in 2023 (WHO, July 2024). Adult vaccines are also gaining attention due to rising bacterial infection prevalence and R&D in adult-targeted vaccines.

By indication, pneumococcal disease led the market, followed by diphtheria/tetanus/pertussis vaccines.

Regional Outlook

North America dominated with USD 15.16 billion in 2024, driven by vaccination programs, strong R&D, and regulatory support. Europe is growing steadily with national immunization programs and centralized vaccine procurement systems. Asia Pacific is the fastest-growing region, led by India and China, supported by local vaccine manufacturers and government campaigns. Latin America and the Middle East & Africa are expanding gradually, bolstered by UNICEF and GAVI vaccination initiatives and the adoption of thermostable vaccines.

Competitive Landscape

Key players include Sanofi (France), GSK plc. (U.K.), Merck & Co., Inc. (U.S.), Bharat Biotech (India), Pfizer Inc. (U.S.), Emergent BioSolutions, Inc. (U.S.), and the Serum Institute of India Pvt. Ltd. These companies focus on R&D, strategic partnerships, and global distribution networks. Notable developments include Pfizer's PREVENAR 20 approval in March 2024 and Merck's Capvaxive pneumococcal vaccine approval in June 2024.

Conclusion

With a market size of USD 27.23 billion in 2024, growing to USD 29.68 billion in 2025 and projected to reach USD 62.66 billion by 2032, the bacterial vaccines market is set for strong growth. Driven by rising bacterial disease prevalence, antimicrobial resistance concerns, technological advancements, and expanding immunization programs, the market offers substantial opportunities for vaccine manufacturers, healthcare providers, and public health organizations globally.

Segmentation By Type

• Recombinant/Conjugate/Subunit
• Inactivated
• Live Attenuated
• Toxoid
• Others

By Route of Administration

• Parenteral
• Oral

By Age Group

• Pediatrics
• Adults

By Indication

• Meningococcal Disease
• Pneumococcal Disease
• Diphtheria/Tetanus/Pertussis
• Others

By Distribution Channel

• Hospital & Retail Pharmacies
• Government Suppliers
• Others

By Geography

• North America (By Type, Route of Administration, Age Group, Indication, Distribution Channel, and Country)
  • U.S.
  • Canada
• Europe (By Type, Route of Administration, Age Group, Indication, Distribution Channel, and Country/Sub-Region)
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Type, Route of Administration, Age Group, Indication, Distribution Channel, and Country/Sub-Region)
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of the Asia Pacific
• Latin America (By Type, Route of Administration, Age Group, Indication, Distribution Channel, and Country/Sub-Region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Type, Route of Administration, Age Group, Indication, Distribution Channel, and Country/Sub-Region)
  • GCC
  • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Incidence/Prevalence of Key Diseases, By Key Countries/Regions, 2024
• 4.2. Pipeline Analysis, By Key Players
• 4.3. Technological Advancements in the Bacterial Vaccines
• 4.4. New Product Launches, By Key Players
• 4.5. Key Industry Developments Such as Mergers, Acquisitions, and Partnerships

5. Global Bacterial Vaccines Market Analysis, Insights and Forecast, 2019-2032

• 5.1. Market Analysis, Insights and Forecast - By Type
  • 5.1.1. Recombinant/Conjugate/Subunit
  • 5.1.2. Inactivated
  • 5.1.3. Live Attenuated
  • 5.1.4. Toxoid
  • 5.1.5. Others
• 5.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 5.2.1. Parenteral
  • 5.2.2. Oral
• 5.3. Market Analysis, Insights and Forecast - By Age Group
  • 5.3.1. Pediatrics
  • 5.3.2. Adolts
• 5.4. Market Analysis, Insights and Forecast - By Indication
  • 5.4.1. Meningococcal Disease
  • 5.4.2. Pneumococcal Disease
  • 5.4.3. Diphtheria/Tetanus/Pertussis
  • 5.4.4. Others
• 5.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.5.1. Hospital & Retail Pharmacies
  • 5.5.2. Government Suppliers
  • 5.5.3. Others
• 5.6. Market Analysis, Insights and Forecast - By Region
  • 5.6.1. North America
  • 5.6.2. Europe
  • 5.6.3. Asia Pacific
  • 5.6.4. Latin America
  • 5.6.5. Middle East & Africa

6. North America Bacterial Vaccines Market Analysis, Insights and Forecast, 2019-2032

• 6.1. Market Analysis, Insights and Forecast - By Type
  • 6.1.1. Recombinant/Conjugate/Subunit
  • 6.1.2. Inactivated
  • 6.1.3. Live Attenuated
  • 6.1.4. Toxoid
  • 6.1.5. Others
• 6.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 6.2.1. Parenteral
  • 6.2.2. Oral
• 6.3. Market Analysis, Insights and Forecast - By Age Group
  • 6.3.1. Pediatrics
  • 6.3.2. Adolts
• 6.4. Market Analysis, Insights and Forecast - By Indication
  • 6.4.1. Meningococcal Disease
  • 6.4.2. Pneumococcal Disease
  • 6.4.3. Diphtheria/Tetanus/Pertussis
  • 6.4.4. Others
• 6.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.5.1. Hospital & Retail Pharmacies
  • 6.5.2. Government Suppliers
  • 6.5.3. Others
• 6.6. Market Analysis, Insights and Forecast - By Country
  • 6.6.1. U.S.
  • 6.6.2. Canada

7. Europe Bacterial Vaccines Market Analysis, Insights and Forecast, 2019-2032

• 7.1. Market Analysis, Insights and Forecast - By Type
  • 7.1.1. Recombinant/Conjugate/Subunit
  • 7.1.2. Inactivated
  • 7.1.3. Live Attenuated
  • 7.1.4. Toxoid
  • 7.1.5. Others
• 7.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 7.2.1. Parenteral
  • 7.2.2. Oral
• 7.3. Market Analysis, Insights and Forecast - By Age Group
  • 7.3.1. Pediatrics
  • 7.3.2. Adolts
• 7.4. Market Analysis, Insights and Forecast - By Indication
  • 7.4.1. Meningococcal Disease
  • 7.4.2. Pneumococcal Disease
  • 7.4.3. Diphtheria/Tetanus/Pertussis
  • 7.4.4. Others
• 7.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.5.1. Hospital & Retail Pharmacies
  • 7.5.2. Government Suppliers
  • 7.5.3. Others
• 7.6. Market Analysis, Insights and Forecast - By Country/Sub-Region
  • 7.6.1. U.K.
  • 7.6.2. Germany
  • 7.6.3. France
  • 7.6.4. Spain
  • 7.6.5. Italy
  • 7.6.6. Scandinavia
  • 7.6.7. Rest of Europe

8. Asia Pacific Bacterial Vaccines Market Analysis, Insights and Forecast, 2019-2032

• 8.1. Market Analysis, Insights and Forecast - By Type
  • 8.1.1. Recombinant/Conjugate/Subunit
  • 8.1.2. Inactivated
  • 8.1.3. Live Attenuated
  • 8.1.4. Toxoid
  • 8.1.5. Others
• 8.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 8.2.1. Parenteral
  • 8.2.2. Oral
• 8.3. Market Analysis, Insights and Forecast - By Age Group
  • 8.3.1. Pediatrics
  • 8.3.2. Adolts
• 8.4. Market Analysis, Insights and Forecast - By Indication
  • 8.4.1. Meningococcal Disease
  • 8.4.2. Pneumococcal Disease
  • 8.4.3. Diphtheria/Tetanus/Pertussis
  • 8.4.4. Others
• 8.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.5.1. Hospital & Retail Pharmacies
  • 8.5.2. Government Suppliers
  • 8.5.3. Others
• 8.6. Market Analysis, Insights and Forecast - By Country/Sub-Region
  • 8.6.1. Japan
  • 8.6.2. China
  • 8.6.3. India
  • 8.6.4. Australia
  • 8.6.5. Southeast Asia
  • 8.6.6. Rest of Asia Pacific

9. Latin America Bacterial Vaccines Market Analysis, Insights and Forecast, 2019-2032

• 9.1. Market Analysis, Insights and Forecast - By Type
  • 9.1.1. Recombinant/Conjugate/Subunit
  • 9.1.2. Inactivated
  • 9.1.3. Live Attenuated
  • 9.1.4. Toxoid
  • 9.1.5. Others
• 9.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 9.2.1. Parenteral
  • 9.2.2. Oral
• 9.3. Market Analysis, Insights and Forecast - By Age Group
  • 9.3.1. Pediatrics
  • 9.3.2. Adolts
• 9.4. Market Analysis, Insights and Forecast - By Indication
  • 9.4.1. Meningococcal Disease
  • 9.4.2. Pneumococcal Disease
  • 9.4.3. Diphtheria/Tetanus/Pertussis
  • 9.4.4. Others
• 9.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.5.1. Hospital & Retail Pharmacies
  • 9.5.2. Government Suppliers
  • 9.5.3. Others
• 9.6. Market Analysis, Insights and Forecast - By Country/Sub-Region
  • 9.6.1. Brazil
  • 9.6.2. Mexico
  • 9.6.3. Rest of Latin America

10. Middle East & Africa Bacterial Vaccines Market Analysis, Insights and Forecast, 2019-2032

• 10.1. Market Analysis, Insights and Forecast - By Type
  • 10.1.1. Recombinant/Conjugate/Subunit
  • 10.1.2. Inactivated
  • 10.1.3. Live Attenuated
  • 10.1.4. Toxoid
  • 10.1.5. Others
• 10.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 10.2.1. Parenteral
  • 10.2.2. Oral
• 10.3. Market Analysis, Insights and Forecast - By Age Group
  • 10.3.1. Pediatrics
  • 10.3.2. Adolts
• 10.4. Market Analysis, Insights and Forecast - By Indication
  • 10.4.1. Meningococcal Disease
  • 10.4.2. Pneumococcal Disease
  • 10.4.3. Diphtheria/Tetanus/Pertussis
  • 10.4.4. Others
• 10.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.5.1. Hospital & Retail Pharmacies
  • 10.5.2. Government Suppliers
  • 10.5.3. Others
• 10.6. Market Analysis, Insights and Forecast - By Country/Sub-Region
  • 10.6.1. GCC
  • 10.6.2. South Africa
  • 10.6.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2024)
• 11.2. Company Profiles
  • 11.2.1. Sanofi
    • 11.2.1.1. Overview
    • 11.2.1.2. Products
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. Financials (Based on Availability)
  • 11.2.2. GSK plc.
    • 11.2.2.1. Overview
    • 11.2.2.2. Products
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. Financials (Based on Availability)
  • 11.2.3. Merck & Co., Inc.
    • 11.2.3.1. Overview
    • 11.2.3.2. Products
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. Financials (Based on Availability)
  • 11.2.4. Bharat Biotech
    • 11.2.4.1. Overview
    • 11.2.4.2. Products
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. Financials (Based on Availability)
  • 11.2.5. Pfizer Inc.
    • 11.2.5.1. Overview
    • 11.2.5.2. Products
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. Financials (Based on Availability)
  • 11.2.6. Emergent BioSolutions, Inc.
    • 11.2.6.1. Overview
    • 11.2.6.2. Products
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. Financials (Based on Availability)
  • 11.2.7. Serum Institute of india Pvt. Ltd.
    • 11.2.7.1. Overview
    • 11.2.7.2. Products
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. Financials (Based on Availability)
  • 11.2.8. BIO-MED
    • 11.2.8.1. Overview
    • 11.2.8.2. Products
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. Financials (Based on Availability)